{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:45:17Z","timestamp":1780983917769,"version":"3.54.1"},"reference-count":0,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":2350,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title><jats:bold>Introduction:<\/jats:bold><\/jats:title><jats:p>Individuals with anxiety disorders often remain symptomatic despite treatment with a first-line pharmacologic agent. More research examining pharmacotherapy augmentation strategies to improve outcomes is needed.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Methods:<\/jats:bold><\/jats:title><jats:p>In an 8-week, open-label, prospective augmentation study, we examined the efficacy and tolerability of the novel antipsychotic agent aripiprazole for adult outpatients with generalized anxiety disorder (n=13) or panic disorder (n=10) who remained symptomatic despite treatment for at least 8 weeks with an adequate (or maximally tolerated) dose of typical pharmacotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Results:<\/jats:bold><\/jats:title><jats:p>Aripiprazole augmentation was associated with a significant reduction in Clinical Global Impressions-Severity scores (paired <jats:italic>t<\/jats:italic>=4.41, <jats:italic>df<\/jats:italic>=22, <jats:italic>P<\/jats:italic>&lt;.001) in the intent-to-treat sample of 23 individuals. Three subjects (13%) discontinued due to sedation, chest discomfort, and restlessness, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Conclusion:<\/jats:bold><\/jats:title><jats:p>These data provide preliminary evidence that aripiprazole may be a useful augmentation strategy for individuals with generalized anxiety disorder or panic disorder who show a limited response to initial pharmacotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s109285290001676x","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T05:00:17Z","timestamp":1470114017000},"page":"522-525","source":"Crossref","is-referenced-by-count":45,"title":["Aripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder"],"prefix":"10.1017","volume":"13","author":[{"given":"Elizabeth A.","family":"Hoge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John J.","family":"Worthington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah R.","family":"Delong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi M.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S109285290001676X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T23:37:01Z","timestamp":1556667421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S109285290001676X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S109285290001676X"],"URL":"https:\/\/doi.org\/10.1017\/s109285290001676x","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}